Unió Europea - estonià - EMA (European Medicines Agency)

medac gesellschaft fuer klinische spezialpraeparate mbh - asparaginaas - prekursorko-lümfoblastne leukeemia-lümfoom - antineoplastilised ained - spectrila on näidustatud osana antineoplastilised kombineeritud ravi ägeda lümfoblastse leukeemia (all lastel alates sünnist kuni 18 aastat ja täiskasvanute) raviks.

Unió Europea - estonià - EMA (European Medicines Agency)

ratiopharm gmbh - paklitakseel - rinnanäärmed - antineoplastilised ained - pazenir monotherapy on näidustatud ravi metastaatilise rinnavähi täiskasvanud patsientidel, kes ei ole suutnud esimese rea raviks metastaatilise haiguse ja kelle jaoks standard, anthracycline sisaldav ravi ei ole näidustatud. pazenir koos carboplatin on näidustatud esimese rea ravi non-small cell lung cancer) täiskasvanud patsientidel, kes ei ole kandidaadid potentsiaalselt tervendav kirurgia ja/või kiiritusravi.

Unió Europea - estonià - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastilised ained - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

Unió Europea - estonià - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leukeemia, karvane rakk - antineoplastilised ained - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Unió Europea - estonià - EMA (European Medicines Agency)

novo nordisk a/s - somapacitan - kasv - hüpofüüsi ja hüpotaalamuse hormoonid ja analoogid - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).

Unió Europea - estonià - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Unió Europea - estonià - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimetüülfumaraat - sclerosis multiplex, relapsing-remitting - immunosupressandid - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Estònia - estonià - Ravimiamet

bayer ag - levonorgestreel - intrauteriinne ravivahend - 19,5mg 1tk; 19,5mg 5tk

Estònia - estonià - Ravimiamet

bayer ag - levonorgestreel - intrauteriinne ravivahend - 52mg 1tk

Estònia - estonià - Ravimiamet

bayer ag - levonorgestreel - intrauteriinne ravivahend - 13,5mg 5tk